This venture player is plotting $200M in new biotech investing — and they’re doubling down on a startup-rich strategy
Eight years ago, the partners at Hatteras Venture Partners reserved 20% of their fund for seed-stage plays. The impact of sequencing was spreading, driving a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
